Generex Provides Update on Generex's Flagship Product Oral-lyn™ in India
WORCESTER, Mass. and TORONTO, June 25, 2012
WORCESTER, Mass. and TORONTO, June 25, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) announced today that it has been provided with an update on the status of the clinical and regulatory program for Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, in India (where the product is branded as Recosulin). The update has been provided by the Company's Indian licensee, Shreya Life Sciences Pvt. Ltd. (www.shreya.co.in).
Shreya is undertaking a Phase III clinical study of Generex Oral-lyn™ as a condition precedent to the entitlement to undertake commercial distribution of the product in India. To date, 125 patients have completed the study at 14 sites in India. Shreya has advised that clinical trials at all sites will be completed by the end of July, 2012, at which point statistical data analysis of the more than 200 patients will be undertaken. Shreya has indicated that, before the end of August, 2012, it expects to submit completed study data to the Central Drugs Standard Control Organization, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India.
Shreya hopes to secure final marketing approval from the Indian government before the end of this year.
"The important information and data collected by Shreya in India will give added support to Oral-lyn™, delivered by the Generex proprietary RapidMist™ platform," stated Dr. James H. Anderson, Jr., MD, FFPM, FACE, Generex' Senior Scientific Advisor. "In conjunction with the scientific data presented at last week's annual meeting of the Generex stockholders, which is available on the Generex website, we will have additional clinical trial evidence of the efficacy of Oral-lyn™ in providing metabolic control to patients along all stages of the continuum of diabetes from impaired glucose tolerance to overt diabetes mellitus. We are committed to providing the best possible formulations of Oral-lyn™ to patients globally, as announced at the recent stockholders' meeting, with our program to increase the convenience, compliance, and safety for patients by producing a more concentrated Oral-lyn™ formulation that would allow dosing in the average patient to be reduced to fewer sprays."
Dr. Anderson continued: "Additional short clinical studies will be designed to demonstrate the potential for Oral-lyn™'s unique pharmacokinetic profile to achieve metabolic results that are not possible with sub-cutaneously injected insulins, even with the rapid acting insulin analogs. These studies will allow our marketing partners to more easily obtain reimbursement over injected insulin, and help insure a more rapid uptake of use by patients and the medical community."
"The new Generex Team is committed to the successful development and commercialization of Oral-lyn™," commented Dr. David Brusegard, PhD, Chief Operating Officer of Generex, "and will deploy a strong scientific and clinical strategy to accomplish that for the benefit of patients worldwide."
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One technology focuses on modification of peptides with Ii-Key to increase potency while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
SOURCE Generex Biotechnology Corporation
Feed from BusinessWire
Panasonic Achieves New Milestone, Reaches 1 Million AC Sales in India
Source: Panasonic India (Business Wire India) On: 20th May, 17:39
ZALP – An Employee Referral Booster that Guarantees to Transform the Recruiting Process of Indian Organizations Like Never Before
Source: Pebstone Infotech (Business Wire India) On: 20th May, 16:00
RED Express Brings Swiftness in the Domestic Express Industry with a Range of Incredible Services
Source: RED Express (Business Wire India) On: 20th May, 15:16
GE Healthcare Launches #GetFit Cancer Prevention Campaign
Source: Business Wire (Business Wire India) On: 20th May, 15:10
S+S X-ray Technology Sets the Standard for Contaminant Detection in the Meat Industry
Source: S+S Separation and Sorting Technology GmbH (Business Wire India) On: 20th May, 14:56
Bloomberg Appoints Samuel Palmisano as Independent Adviser
Source: Business Wire (Business Wire India) On: 20th May, 10:30
‘.IN.NET’ – New Internet Address for India, Launching June 17th
Source: Business Wire (Business Wire India) On: 20th May, 10:05
5th National Annual Survey on ESOPs from ESOP Direct
Source: ESOP Direct (Business Wire India) On: 20th May, 09:30
Delta Displays Brings Real-Time Visibility to High-Tech Crime Center
Source: Delta (Business Wire India) On: 17th May, 17:43
2013 Frost & Sullivan India ICT Awards sees Tata Communications take Four Awards in the Enterprise Telecom Services Category
Source: Frost & Sullivan (Business Wire India) On: 17th May, 17:13
Feed from PR Newswire
Milnaa.com Re-launches as India\'s Premier Communications, Media and Entertainment Destination
Source: Milnaa Media Pvt Ltd On: 20th May, 07:11 AM
Eversheds Launches Beijing Office With Two New Partner Hires
Source: Eversheds On: 20th May, 06:29 AM
Value Edge launches Pharma Analytics Blog, Pharma Musings
Source: Value Edge Research Services Pvt. Ltd On: 20th May, 05:00 AM
Matrix Cellular Launches Gamut of Offers for International Travelers This Summer Season
Source: Matrix Cellular (International) Services Pvt. Ltd. On: 20th May, 04:41 AM
Sony Mobile's Xperia Tablet Z™ Now Available Worldwide
Source: Sony Mobile Communications AB On: 20th May, 04:00 AM
Artha Venture Challenge Invites Social Ventures to Access Rs. 25 Lakh of Matched Funding
Source: Artha Platform On: 20th May, 03:00 AM
Aspect Software Selects Tech Mahindra as its \'Channel Partner\' for APAC and EMEA
Source: Aspect Software On: 20th May, 02:14 AM
Keeler Launches its New Symphony Slit Lamp
Source: Keeler On: 20th May, 12:30 AM
EnKing International Purchasing Carbon Credits From UNFCCC-CDM Program @ 5 Euros per Credit
Source: EKI Energy Services Limited On: 20th May, 12:30 AM
Chic Weeks: A Collaboration Between the Chic Outlet Shopping® Villages, Black Tomato and PINCH Magazine
Source: Value Retail PLC On: 17th May, 02:29 PM
- Is the interest in Gold ETFs waning?
- Do FIIs buy high and sell low – I? Maximum buying at peak index levels
- OMCs to stop LPG deliveries to houses with multiple-connections from 1st June
- COMPAT orders cement cos to pay 10% of the Rs6,307 crore penalty
- Sun TV Networks announces 11% jump in its net profit
- S&P cautions India of rating downgrade; retains negative outlook
- BSE to shift 29 scrips to T group category for failure to comply with demat norms
- ITC net profit up 19.4%, aided by non-cigarette and agri-business segments
- Vikram Pandit to buy stake in JM Financial, to head its proposed banking arm
- MMM India, another MLM taking people for “double-your-money” ride
- RBI tells HDFC Bank not to make up its own KYC verification rules
- Why I-T returns of Pawar, Jindal and Gandhi are exempted from RTI?
- The draconian LBT: Local Body Tax explained
- How much longer can the FM, RBI ignore HSBC in India?
- Aadhaar: Private ownership of UID data- Part I
- Aadhaar: Who owns the UID database? –Part II
- Did HSBC Bank resort to toxic churning and illegitimate transactions to earn commissions?
- PNB Metlife refunds Rs25,000 to the correct policyholder: another Moneylife victory
- The draconian LBT: Local Body Tax explained
- Goa’s Advocate General is the highest paid across the country, reveals RTI
- Mass mis-selling: 59,000 investors in Kolhapur are alleged to have lost money in LIC ULIPs
- Do FIIs buy high and sell low – I? Maximum buying at peak index levels
- Investors lost Rs1 lakh crore due to poor regulation. Will there be a CBI probe?
- High Mark to sell 250 million records to another credit bureau?
- Directors of public sector banks: The ground reality
- System glitch deducts 40% amount as TDS from SBI depositors’ account!
- Do FIIs buy high and sell low–II? Momentum-chasing
What's your say?
What you said
Thanks for casting your votes! View Previous Polls
Join 22, 000 Others
- Daily & Weekly newsletters
- Access to www.moneylife.in to comment, create alerts
- Your own profile in Moneylife.in
- All special mailers
- Basic membership to MSSN, our new initiative
- Free ebooks
- Invitation to events
- Invitation to round-table meets
- Access to Insurance helpline
- Access to counselling sessions
- Access to Reading room in Mumbai